Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Eli Lilly and Company
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 5 ans
A Study in advanced squamous non small cell lung cancer
The primary objective of this study is to estimate the best objective response rates (ORR; complete response [CR] + partial response [PR]) associated with gemcitabine-cisplatin plus necitumumab in che...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company Ltd
Update Il y a 5 ans
Long-Term Treatment with Exenatide versus Glimepiride in Patients with Type 2 Diabetes Pretreated with Metformin
The primary objective of this study is to test the hypothesis that exenatide injected twice daily is non-inferior to glimepiride given once daily before breakfast (titrated up to the maximally tolerat...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 5 ans
A Study of Ixekizumab in Participants With Active Psoriatic Arthritis Un estudio de Ixekizumab in participantes con Artritis Psoriasica activa
The primary objective of the study is to compare ixekizumab 80 mg Q2W with placebo in maintenance of treatment response, as measured by the time to relapse during the randomized double-blind withdrawa...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 5 ans
Protocol B4Z-MC-LYDO(b) Maintenance of Response After Open-Label Treatment with Atomoxetine Hydrochloride in Adult Outpatients with Attention-Deficit/Hyperactivity Disorder (ADHD): A Placebo-Controlled, Randomized Withdrawal Study
The primary objective of Study LYDO is to test the hypothesis that atomoxetine is superior to placebo in maintaining a satisfactory response at the end of double-blind treatment in adult outpatients w...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 5 ans
A Phase 3 Study in Moderate to Severe Rheumatoid Arthritis
Determine whether baricitinib is superior to placebo in the treatment of patients with moderately to severely active RA despite MTX treatment (i.e., MTX IR), as assessed by the proportion of patients ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 5 ans
A Randomized, Placebo-controlled, Double-blind Study of LY2216684 Fixed-dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
The primary objective of this study is to assess whether at least one dose of LY2216684 (12 mg or 18 mg once daily [QD]) is superior to placebo QD in the adjunctive treatment of patients with major de...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 5 ans
A Phase 2 Study of Multiple Intravenous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis on Concomitant Methotrexate and an Inadequate Response to TNFα Inhibitor Therapy
To evaluate LY2127399 efficacy assessed by the proportion of patients who achieve an ACR50 response compared to placebo at 16 weeks in patients with RA, who have had an inadequate response or intolera...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company Limited
Update Il y a 5 ans
F1D-MC-HGLQ A Randomized, Open-Label Study Comparing the Effects of Olanzapine Pamoate Depot with Oral Olanzapine on Treatment Outcomes in Outpatients with Schizophrenia
The primary objective of the study F1D-MC-HGLQ is to assess the time to all-cause discontinuation in outpatients with schizophrenia who are at risk for relapse, as demonstrated by at least two episode...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Eli Lilly and Company
Update Il y a 6 ans
Étude I4D-MC-JTJI : étude de phase 1b non-randomisée visant à déterminer la sécurité et la dose recommandée du prexasertib en association avec le cisplatine et la radiothérapie ou avec le cetuximab et la radiothérapie chez des patients ayant un cancer de la tête ou du cou localement avancé.
Les cancers de l’oropharynx, du pharynx et du larynx constituent 90% des cancers de la tête et du cou et sont favorisés par le tabagisme et l’abus d’alcool. Leur traitement est complexe et dépend des ...
Country
France
organs
Tête et cou
Specialty
Thérapies Ciblées
,
Chimiothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Eli Lilly and Company Limited
Update Il y a 5 ans
A Randomized Phase 3 Study of Enzastaurin versus Lomustine in the Treatment of Recurrent, Intracranial Glioblastoma Multiforme
The primary objective is to compare enzastaurin versus lomustine in terms of PFS time in patients with recurrent, intracranial GBM (WHO Stage IV).
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
14
15
16
17
18
19
20
21
22
23
Next